| Literature DB >> 34960130 |
Joanna Gotlib1, Mariusz Jaworski1, Dominik Wawrzuta1, Tomasz Sobierajski2, Mariusz Panczyk1.
Abstract
The COVID-19 pandemic had a huge impact on the mental health of people around the world, and it increased the level of fear of infection and anxiety about the consequences of the disease caused by the SARS-CoV-2 virus. We examined the relationship between the level of anxiety among nursing students and their knowledge about COVID-19 vaccination. In addition, we explored the correlations among the level of anxiety, knowledge about vaccination, and the willingness to vaccinate against COVID-19. A total of 790 undergraduate nursing students participated in the study. The results demonstrated that the level of anxiety among the surveyed nursing students was low; 40% of the study participants did not report any anxiety at all, 30% reported mild anxiety, 20% reported moderate anxiety, and 9% reported severe anxiety. At the time of the study, 77.2% of the participants were already vaccinated against COVID-19. Student knowledge about vaccination against COVID-19 was high and anxiety levels were low, with no direct correlation between the knowledge of vaccination and the severity of anxiety.Entities:
Keywords: COVID-19 vaccine; GAD-7; anxiety; knowledge; undergraduate nursing students
Year: 2021 PMID: 34960130 PMCID: PMC8703418 DOI: 10.3390/vaccines9121385
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Characteristics of study group (N = 790).
| Nursing Department | |
| Pomeranian Medical University | 238 (30.1) |
| Medical University of Warsaw | 114 (14.4) |
| Medical University of Gdańsk | 86 (10.9) |
| Jagiellonian University Medical College | 65 (8.2) |
| Poznan University of Medical Sciences | 61 (7.7) |
| Medical University of Lodz | 46 (5.8) |
| Wroclaw Medical University | 39 (4.9) |
| Medical University of Białystok | 36 (4.6) |
| Medical University of Lublin | 35 (4.4) |
| Medical University of Silesia | 33 (4.2) |
| Jan Kochanowski University Medical College | 20 (2.5) |
| University of Physical Education in Warsaw | 17 (2.2) |
| Year of Study, | |
| 1 | 316 (40.0) |
| 2 | 331 (41.9) |
| 3 | 143 (18.1) |
| Gender, | |
| Female | 721 (91.3) |
| Male | 57 (7.2) |
| Refusal to answer | 12 (1.5) |
| Age (Years) | |
| M ± SD | 22.4 ± 5.00 |
| Range | 19.0–53.0 |
| Residence, | |
| Alone | 101 (12.8) |
| With relatives/family/friends (excluding seniors) | 550 (69.6) |
| With relatives/family/friends (including seniors) | 139 (17.6) |
| Living with a person at higher risk of COVID-19, | |
| Yes | 234 (29.6) |
| No | 556 (70.4) |
| COVID-19 infection from people in the immediate environment, | |
| Yes, acute or very acute | 179 (22.7) |
| Yes, but rather mild | 390 (49.4) |
| No | 171 (21.6) |
| I do not know | 50 (6.3) |
| COVID-19 infection, | |
| Yes (acute symptoms of infection) | 21 (2.7) |
| Yes (mild symptoms of infection) | 71 (9.0) |
| Yes (no symptoms of infection) | 11 (1.4) |
| Probably (no test confirmation) | 174 (22.0) |
| No | 333 (42.2) |
| I do not know | 180 (22.8) |
M—mean; SD—standard deviation.
Figure 1Distribution of GAD-7 scoring (N = 790).
Anxiety level and willingness to get a COVID-19 vaccine.
| No Anxiety | Mild Anxiety | Moderate Anxiety | Severe Anxiety |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | |||
| Vaccination against COVID-19 | ||||||||||
| No | 76 | 23.7 | 56 | 23.7 | 33 | 20.6 | 13 | 18.3 | 8.807 | 0.185 |
| Yes, mRNA | 189 | 58.9 | 136 | 57.6 | 111 | 69.4 | 46 | 64.8 | ||
| Yes, vector-based vaccine | 56 | 17.4 | 44 | 18.6 | 16 | 10.0 | 12 | 16.9 | ||
| Selected vaccination site | ||||||||||
| Workplace | 24 | 9.8 | 21 | 11.7 | 13 | 10.2 | 7 | 12.1 | 4.959 | 0.549 |
| University | 199 | 81.2 | 147 | 81.7 | 110 | 86.6 | 47 | 81.0 | ||
| Other | 22 | 9.0 | 12 | 6.7 | 4 | 3.1 | 4 | 6.9 | ||
* Chi-squared test.
Anxiety level and access to current information on vaccination at university.
| No Anxiety | Mild Anxiety | Moderate Anxiety | Severe Anxiety |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | |||
| Has the university provided access to up-to-date knowledge on vaccination? | ||||||||||
| Yes | 132 | 41.0 | 104 | 43.9 | 59 | 37.1 | 23 | 32.4 | 10.500 | 0.105 |
| No | 108 | 33.5 | 74 | 31.2 | 65 | 40.9 | 35 | 49.3 | ||
| I do not know | 82 | 25.5 | 59 | 24.9 | 35 | 22.0 | 13 | 18.3 | ||
* Chi-squared test.
Frequency of use of sources of information on vaccination and anxiety levels.
| No Anxiety | Mild Anxiety | Moderate Anxiety | Severe Anxiety |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M | SD | M | SD | M | SD | M | SD | |||
| (a) Websites of institutions and organizations related to health protection | 3.33 | 1.95 | 3.36 | 1.85 | 3.45 | 1.80 | 3.63 | 1.98 | 0.595 | 0.618 |
| (b) Non-health-related websites | 1.79 | 1.69 | 2.06 | 1.79 | 2.05 | 1.77 | 2.04 | 1.79 | 1.519 | 0.208 |
| (c) Specialized professional journals (online and in paper) | 2.09 | 2.00 | 2.59 | 1.89 | 2.47 | 1.89 | 2.89 | 2.13 | 4.911 | 0.002 |
| (d) Social media | 2.49 | 1.94 | 2.91 | 1.98 | 2.87 | 1.92 | 2.86 | 2.02 | 2.675 | 0.046 |
| (e) Blogs and vlogs of healthcare specialists | 2.26 | 2.06 | 2.84 | 1.99 | 2.67 | 2.09 | 3.10 | 2.04 | 5.451 | 0.001 |
| (f) Non-specialist blogs and vlogs | 0.64 | 1.16 | 0.97 | 1.50 | 0.81 | 1.26 | 1.03 | 1.47 | 3.741 | 0.011 |
| (g) Web portals (e.g., Onet and Wirtualna Polska) | 1.48 | 1.67 | 1.67 | 1.71 | 1.78 | 1.82 | 1.59 | 1.65 | 1.289 | 0.277 |
| (h) Radio/television | 1.94 | 1.88 | 2.15 | 1.87 | 2.15 | 1.94 | 1.96 | 1.90 | 0.756 | 0.519 |
| (i) Classes at university | 3.05 | 1.81 | 3.13 | 1.84 | 3.16 | 2.01 | 2.77 | 1.83 | 0.823 | 0.481 |
| (j) Workplace | 1.50 | 2.13 | 1.70 | 2.12 | 1.88 | 2.32 | 1.80 | 2.32 | 1.212 | 0.304 |
| (k) Other students at university | 2.29 | 1.82 | 2.70 | 1.68 | 2.66 | 1.73 | 2.82 | 1.93 | 3.739 | 0.011 |
| (l) Colleagues | 1.35 | 2.00 | 1.53 | 1.96 | 1.66 | 2.06 | 1.52 | 2.14 | 0.918 | 0.432 |
| (m) Family/friends not related to health protection | 1.58 | 1.78 | 1.79 | 1.72 | 1.70 | 1.69 | 1.75 | 2.01 | 0.728 | 0.535 |
* One-way ANOVA.
Knowledge about vaccination and anxiety levels.
| Statement | No Anxiety | Mild Anxiety | Moderate Anxiety | Severe Anxiety |
| |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | |||
| After recovering from COVID-19 infection, vaccination is no longer necessary | ||||||||||
| Incorrect | 40 | 14.3 | 25 | 10.7 | 14 | 8.5 | 12 | 10.8 | 3.811 | 0.283 |
| Correct | 239 | 85.7 | 209 | 89.3 | 150 | 91.5 | 99 | 89.2 | ||
| mRNA vaccines contain viral particles. | ||||||||||
| Incorrect | 166 | 59.5 | 137 | 58.5 | 106 | 65.0 | 59 | 53.6 | 3.727 | 0.292 |
| Correct | 113 | 40.5 | 97 | 41.5 | 57 | 35.0 | 51 | 46.4 | ||
| You should avoid contact with people at higher risk of COVID-19 illness for 24 h after COVID-19 vaccination, as there is a possibility of infecting them with viral particles from the vaccine | ||||||||||
| Incorrect | 88 | 31.5 | 66 | 28.2 | 52 | 31.7 | 30 | 27.3 | 1.292 | 0.731 |
| Correct | 191 | 68.5 | 168 | 71.8 | 112 | 68.3 | 80 | 72.7 | ||
| A person vaccinated with two doses no longer needs to wear a face mask | ||||||||||
| Incorrect | 30 | 10.8 | 21 | 9.0 | 16 | 9.8 | 11 | 9.9 | 0.456 | 0.928 |
| Correct | 249 | 89.2 | 213 | 91.0 | 148 | 90.2 | 100 | 90.1 | ||
| It was proven that, as with other vaccinations, vaccine protection against SARS-CoV-2 is life-long | ||||||||||
| Incorrect | 53 | 19.0 | 47 | 20.1 | 38 | 23.2 | 24 | 21.6 | 1.211 | 0.750 |
| Correct | 226 | 81.0 | 187 | 79.9 | 126 | 76.8 | 87 | 78.4 | ||
| When vaccinating, vaccines from two different manufacturers can be used for the first- and second-dose administrations of the vaccine | ||||||||||
| Incorrect | 43 | 15.4 | 29 | 12.4 | 24 | 14.6 | 13 | 11.7 | 1.498 | 0.683 |
| Correct | 236 | 84.6 | 205 | 87.6 | 140 | 85.4 | 98 | 88.3 | ||
| Complete vaccination protection develops within 7–14 days after the second dose of the vaccine was administered | ||||||||||
| Incorrect | 91 | 32.6 | 69 | 29.5 | 50 | 30.5 | 41 | 36.9 | 2.141 | 0.544 |
| Correct | 188 | 67.4 | 165 | 70.5 | 114 | 69.5 | 70 | 63.1 | ||
| After reaching the threshold of herd immunity, COVID-19 will most likely become one of the seasonal diseases | ||||||||||
| Incorrect | 95 | 34.1 | 98 | 41.9 | 61 | 37.2 | 49 | 44.1 | 5.075 | 0.166 |
| Correct | 184 | 65.9 | 136 | 58.1 | 103 | 62.8 | 62 | 55.9 | ||
| Currently, only mRNA vaccines are marketed in the European Union | ||||||||||
| Incorrect | 77 | 27.6 | 63 | 27.0 | 49 | 29.9 | 28 | 25.2 | 0.776 | 0.855 |
| Correct | 202 | 72.4 | 170 | 73.0 | 115 | 70.1 | 83 | 74.8 | ||
| The pandemic will continue until more than 40% of the population has become immunized naturally (through disease) or artificially (through vaccination) | ||||||||||
| Incorrect | 195 | 69.9 | 161 | 69.1 | 115 | 70.1 | 74 | 67.3 | 0.315 | 0.957 |
| Correct | 84 | 30.1 | 72 | 30.9 | 49 | 29.9 | 36 | 32.7 | ||
* Chi-squared test.
Contraindications to vaccination and anxiety levels.
| No Anxiety | Mild Anxiety | Moderate Anxiety | Severe Anxiety |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | |||
| Patients after cell, tissue, and organ transplants | ||||||||||
| No | 109 | 39.1 | 107 | 45.7 | 72 | 43.9 | 48 | 43.2 | 2.490 | 0.477 |
| Yes | 170 | 60.9 | 127 | 54.3 | 92 | 56.1 | 63 | 56.8 | ||
| Dialysis patients | ||||||||||
| No | 192 | 68.8 | 168 | 71.8 | 110 | 67.1 | 80 | 72.1 | 1.420 | 0.701 |
| Yes | 87 | 31.2 | 66 | 28.2 | 54 | 32.9 | 31 | 27.9 | ||
| Patients with neoplastic diseases | ||||||||||
| No | 149 | 53.4 | 109 | 46.6 | 85 | 51.8 | 66 | 59.5 | 5.446 | 0.142 |
| Yes | 130 | 46.6 | 125 | 53.4 | 79 | 48.2 | 45 | 40.5 | ||
| Pregnant women | ||||||||||
| No | 124 | 44.4 | 101 | 43.2 | 73 | 44.5 | 52 | 46.8 | 0.415 | 0.937 |
| Yes | 155 | 55.6 | 133 | 56.8 | 91 | 55.5 | 59 | 53.2 | ||
| Breastfeeding women | ||||||||||
| No | 161 | 57.7 | 122 | 52.1 | 91 | 55.5 | 68 | 61.3 | 3.010 | 0.390 |
| Yes | 118 | 42.3 | 112 | 47.9 | 73 | 44.5 | 43 | 38.7 | ||
| Patients requiring prolonged mechanical ventilation | ||||||||||
| No | 209 | 74.9 | 169 | 72.2 | 120 | 73.2 | 80 | 72.1 | 0.595 | 0.898 |
| Yes | 70 | 25.1 | 65 | 27.8 | 44 | 26.8 | 31 | 27.9 | ||
| Patients with hypersensitivity to vaccine components | ||||||||||
| No | 29 | 10.4 | 16 | 6.8 | 16 | 9.8 | 7 | 6.3 | 3.079 | 0.380 |
| Yes | 250 | 89.6 | 218 | 93.2 | 148 | 90.2 | 104 | 93.7 | ||
* Chi-squared test.